UPCC 04923: A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malig
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to the Protocol, Section 2.1 (Objectives) Please refer to the Protocol, Section 2.2 (Endpoints) Please refer to the Protocol, Section 2.2 (Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 853190
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
